Suppr超能文献

达那唑:获得性无巨核细胞性血小板减少性紫癜的一种有效治疗选择。

Danazol: an effective option in acquired amegakaryocytic thrombocytopaenic purpura.

作者信息

Mulroy E, Gleeson S, Chiruka S

机构信息

Department of Haematology, Dunedin Hospital, Great King Street, Dunedin 9016, New Zealand.

出版信息

Case Rep Hematol. 2015;2015:171253. doi: 10.1155/2015/171253. Epub 2015 Apr 5.

Abstract

Acquired amegakaryocytic thrombocytopaenic purpura (AATP) is a rare haematological condition characterised by isolated thrombocytopaenia with normal other cell lines. It is often initially misdiagnosed as immune thrombocytopaenic purpura but has characteristic bone marrow findings of reduced megakaryocyte numbers. The optimal treatment of AATP is not clearly defined but revolves around immunosuppressive therapies. We report a case of successful treatment of AATP with danazol, an antioestrogenic medication. We also review the aetiologies and pathogenesis of the disorder and suggest that danazol should be considered as an effective alternative to potent immunosuppression in AATP.

摘要

获得性无巨核细胞性血小板减少性紫癜(AATP)是一种罕见的血液系统疾病,其特征为单纯血小板减少,其他细胞系正常。该病起初常被误诊为免疫性血小板减少性紫癜,但具有巨核细胞数量减少的特征性骨髓表现。AATP的最佳治疗方法尚无明确定义,但主要围绕免疫抑制疗法展开。我们报告了一例使用抗雌激素药物达那唑成功治疗AATP的病例。我们还回顾了该疾病的病因和发病机制,并建议达那唑应被视为AATP有效替代强效免疫抑制治疗的药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a6d/4402186/3be6ffe22ade/CRIHEM2015-171253.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验